New pill takes on tough cancers: first human trial begins
NCT ID NCT06403436
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a first-in-human trial, so the effects are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier Universitaire Vaudois
Lausanne, 1890, Switzerland
-
Ente Ospedaliero Cantonale
Bellinzona, 6500, Switzerland
-
NEXT Oncology Barcelona
Barcelona, 08023, Spain
-
NEXT Oncology Madrid
Madrid, 28223, Spain
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee, 37203, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, 08035, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TT125-802 (a drug taken by mouth)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) and small study (50 people), so the drug may not prove safe or effective. Side effects are unknown and could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.